|
SHIELD
Shock Inhibition Evaluation with Azimilide
Ongoing trial
 |
Author(s) |
Pratt CM, Dorian P, Al-Khalidi HR, Brum JM, Borggrefe M, Tatla DS, Brachmann J, Myerburg RJ, Cannom DS, Holroyde MJ, van der Laan M, Hohnloser SH |
 |
Title(s) |
Design of the SHock Inhibition Evaluation with Azimilide (SHIELD) study: a novel method to assess antiarrhythmic drug effect in patients with an implantable cardioverter-defibrillator |
|
Reference(s) |
Am J Cardiol 2005;95:274–6 |
|
Disease |
Arrhythmia |
|
Purpose |
To evaluate the effects of azimilide on the symptomatic ventricular arrhythmia burden in patients with implantable cardioverter-defibrillators (ICDs) |
|
Study design |
Randomised, double-blind, placebo-controlled, parallel-group |
|
Follow-up |
Aim 1 year |
|
Patients |
Aim 624 patients with ICDs capable of arrhythmia discrimination algorithms (high rate, sudden onset, rate stability) |
|
Treatment regimen |
Azimilide, 75 or 125 mg/day, or placebo |
|
Results |
Not yet available |
|
|
|
